Cite this answer
Calcitonin: quick citable summary
Calcitonin is listed by PeptaHub as a other peptide with a prescription legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Calcitonin: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/calcitonin. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/calcitonin.
What is Calcitonin?
Calcitonin (Miacalcin) is an FDA-approved 32-amino acid peptide hormone that inhibits osteoclast activity to reduce bone resorption. Used for osteoporosis, Paget's disease, and acute hypercalcemia, it also provides central analgesic effects for bone pain.
Overview
Calcitonin (Miacalcin) is an FDA-approved 32 amino acid polypeptide hormone used for the treatment of postmenopausal osteoporosis, Paget's disease of bone, and hypercalcemia. The commercially used form is synthetic salmon calcitonin, which is approximately 40–50 times more potent than human calcitonin on a weight basis and has a longer duration of action, making it clinically preferable.
Mechanism of action
Calcitonin binds to specific calcitonin receptors (CTRs) expressed predominantly on osteoclasts, the bone-resorbing cells. Receptor activation via Gs-coupled cAMP signaling and Gq-coupled phospholipase C activation leads to a rapid cytoskeletal reorganization in osteoclasts — the ruffled border retracts and the cell loses its characteristic polarized morphology. This functional inactivation halts the secretion of hydrochloric acid and cathepsin K that drive bone matrix dissolution. With sustained exposure, osteoclast cell numbers also decrease. The net effect is reduced bone resorption and a fall in serum calcium and phosphate. In the kidney, calcitonin promotes renal excretion of calcium, phosphate, sodium, magnesium, and potassium by inhibiting tubular reabsorption. Calcitonin also has central analgesic properties, mediated through elevated beta-endorphin levels, contributing to its use in Paget's disease-associated bone pain.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| postmenopausal osteoporosis | nasal | 200–200 IU | once daily, alternating nostrils | Administer with calcium and vitamin D supplementation. Alternate nostrils daily. Monitor nasal mucosa. Not first-line; consider bisphosphonates or denosumab first. |
| Paget's disease or hypercalcemia | subcutaneous | 50–100 IU | once daily or every other day | For Paget's disease: 100 IU/day SC; may reduce to 50 IU every 1–3 days after response. For hypercalcemia: 4 IU/kg IM/SC every 12 hours; escalate to 8 IU/kg if needed. |
| hypercalcemia (acute) | intramuscular | 4–8 IU/kg | every 12 hours | Start at 4 IU/kg every 12 hours IM/SC. If inadequate response after 2 days, increase to 8 IU/kg every 12 hours. Maximum 8 IU/kg every 6 hours. Short-term use in acute setting. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Calcitonin research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? Use the peptide dose unit converter for educational calculation support.
Research summary
The PROOF study (5 years, 1,255 postmenopausal women) demonstrated that 200 IU/day intranasal calcitonin reduced vertebral fracture risk by 33% compared to placebo. Lumbar spine bone mineral density increased modestly (+1.5% over 5 years). However, subsequent reviews by the FDA (2013) identified a possible increased risk of malignancy with long-term use, leading to a label update. Calcitonin is no longer a first-line agent for osteoporosis — bisphosphonates and denosumab are preferred — but it retains a role in acute hypercalcemia and Paget's disease management.[1][2][3][4][5]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Calcitonin for synergistic effects.
Legal status
FDA-approved for postmenopausal osteoporosis, Paget's disease, and hypercalcemia. Available as nasal spray (200 IU/day) and subcutaneous/intramuscular injection. The FDA updated the label in 2013 noting a possible association with malignancy on long-term use. Not a controlled substance.
Sourcing & access
Prescription required
Calcitonin is an FDA-approved prescription medication available through licensed healthcare providers, pharmacies, and label-appropriate access programs; compounded access depends on current FDA shortage status and compounding rules.
Frequently asked questions
Calcitonin is FDA-approved for postmenopausal osteoporosis, Paget's disease of bone, and hypercalcemia. It is available as a nasal spray (200 IU daily) for osteoporosis and as an injection for Paget's disease and acute hypercalcemia.
No, calcitonin is no longer first-line for osteoporosis. Bisphosphonates and denosumab are preferred. The FDA updated the calcitonin label in 2013 noting a possible association with malignancy on long-term use, further limiting its role in chronic management.
Synthetic salmon calcitonin is approximately 40 to 50 times more potent than human calcitonin on a weight basis and has a longer duration of action, making it the commercially preferred form for all FDA-approved indications.
Yes, calcitonin has central analgesic properties mediated through elevated beta-endorphin levels. This makes it particularly useful for Paget's disease-associated bone pain, where it provides both pain relief and disease-modifying effects.
Nasal spray side effects include rhinitis and nasal irritation. Injectable forms cause nausea, facial flushing, and injection site inflammation. Long-term use carries a possible increased malignancy risk per FDA label updates.
Research references
- A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study GroupPubMed
- Calcitonin for osteoporosis and bone painPubMed
- Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical studyPubMed
- Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral densityPubMed
- A Randomized Placebo-Controlled Trial Evaluating the Analgesic Effect of Salmon Calcitonin in Refractory Bone Metastasis PainPubMed